---
title: "ENDRA swings to Q2 FY26 net income of $159,944; other income rises to $1.64 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295970379.md"
description: "ENDRA Life Sciences reported a Q2 FY26 net income of $159,944, reversing prior-year losses, driven by $1.64 million in other income including digital asset gains. General and administrative expenses rose 46% to $1.24 million, while R&D and sales/marketing costs fell significantly. The company holds $5.54 million in cash and entered a merger agreement with ASP Isotopes’ Noble Africa, targeting $50 million in gross proceeds."
datetime: "2026-08-14T20:11:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295970379.md)
  - [en](https://longbridge.com/en/news/295970379.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295970379.md)
generator: "portal-rs"
---

# ENDRA swings to Q2 FY26 net income of $159,944; other income rises to $1.64 million

-   ENDRA posted net income of $159,944, swinging from a net loss in the prior-year quarter, as other income climbed to $1.64 million. \* General and administrative expense rose 46% to $1.24 million, while research and development expense fell 39% to $233,665. \* Sales and marketing expense dropped 92% to $5,813; other income reflected $1.7 million in digital asset fair-value gains. \* Cash totaled $5.54 million, including about $3.8 million in restricted cash tied to the May 2026 private placement. \* Entered a merger agreement with ASP Isotopes’ Noble Africa; Noble investment targets about $50 million in gross proceeds before closing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ENDRA Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-090027), on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [NDRA.US](https://longbridge.com/en/quote/NDRA.US.md)
- [ASPI.US](https://longbridge.com/en/quote/ASPI.US.md)
- [29273B500.US](https://longbridge.com/en/quote/29273B500.US.md)

## Related News & Research

- [ASP Isotopes unit amends Standard Bank term loan to ZAR 230.53 million](https://longbridge.com/en/news/296537849.md)
- [ASP Isotopes sets first Capital Markets Day in London](https://longbridge.com/en/news/296487684.md)
- [Charles River Labs director Nancy C. Andrews disposes of 573 common shares worth $163,442.52](https://longbridge.com/en/news/296533503.md)
- [Adaptive Biotechnologies director Peter M. Neupert disposes of 124,690 common shares for $3.14 million](https://longbridge.com/en/news/296412930.md)
- [Medpace director Fred B. Davenport Jr disposes of 7,283 common shares for $4.41 million](https://longbridge.com/en/news/296649041.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**